<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Synovial sarcoma recurrent &#8211; European Clinical Trials Information Network</title>
	<atom:link href="https://clinicaltrials.eu/meddra_pt/synovial-sarcoma-recurrent/feed/" rel="self" type="application/rss+xml" />
	<link>https://clinicaltrials.eu</link>
	<description>Bridging Patients with Clinical Trials</description>
	<lastBuildDate>Tue, 02 Jun 2026 12:24:45 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png</url>
	<title>Synovial sarcoma recurrent &#8211; European Clinical Trials Information Network</title>
	<link>https://clinicaltrials.eu</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Study of Trabectedin alone versus Trabectedin with tTF-NGR combination therapy in adults with metastatic or refractory soft tissue sarcoma who failed first-line treatment</title>
		<link>https://clinicaltrials.eu/trial/study-on-trabectedin-and-ttf-ngr-for-patients-with-metastatic-or-refractory-soft-tissue-sarcoma/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Wed, 29 Apr 2026 14:59:55 +0000</pubDate>
				<guid isPermaLink="false">https://clinicaltrials.eu/trial/study-on-trabectedin-and-ttf-ngr-for-patients-with-metastatic-or-refractory-soft-tissue-sarcoma/</guid>

					<description><![CDATA[This clinical trial studies a treatment for soft tissue sarcoma, a type of cancer that develops in soft tissues like muscles and fat. The study focuses on patients whose cancer has spread to other parts of the body (metastatic) or who did not respond well to previous treatments. The trial compares two treatment approaches: one [&#8230;]]]></description>
										<content:encoded><![CDATA[<p>This clinical trial studies a treatment for <b>soft tissue sarcoma</b>, a type of cancer that develops in soft tissues like muscles and fat. The study focuses on patients whose cancer has spread to other parts of the body (metastatic) or who did not respond well to previous treatments. The trial compares two treatment approaches: one using only <b>trabectedin</b> (a chemotherapy medication) and another combining trabectedin with <b>tTF-NGR</b> (an experimental drug).</p>
<p>The study aims to determine if adding tTF-NGR to standard trabectedin treatment helps keep the cancer under control for a longer time. Both medications are given through an <b>intravenous</b> infusion directly into the bloodstream. The experimental drug tTF-NGR is designed to concentrate the chemotherapy medication inside the tumor.</p>
<p>During the study, participants receive treatment for up to 360 days. Some patients will receive only trabectedin, while others will receive both trabectedin and tTF-NGR. Regular medical examinations and imaging tests will be performed to monitor how the cancer responds to the treatment. The study focuses on patients whose tumors show a specific characteristic called <b>CD13 positivity</b>, which is determined through laboratory testing.</p>
]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
